HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ZO skin suit

This article was originally published in The Rose Sheet

Executive Summary

Prescription skin care firm Obagi Medical Products' motion to dismiss anti-competitive claims by ZO Skin Health was rejected by a Los Angeles County Superior Court in a written opinion July 26, ZO Skin Health announces July 27. A trial date is set for February 2011. In denying OMP's motion, the court stated that "the moral blame attached to the defendant's conduct sufficiently relates to violating laws of free competition" and "the closeness of the connection between the defendant's conduct and the injury suffered is clear." ZO Skin Health, which markets dermatologist Dr. Zein Obagi's retail skin care products, filed suit in January challenging OMP's practices, including efforts to prevent ZO from marketing a new non-prescription skin care line (1"The Rose Sheet" Jan. 11, 2010, In Brief). Obagi founded Worldwide Products Distribution, a firm that later formed the core of OMP, in 1988

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel